Quality Regulation and Competition: Evidence from Pharmaceutical Markets
74 Pages Posted: 9 Oct 2018 Last revised: 9 Nov 2018
There are 2 versions of this paper
Quality Regulation and Competition: Evidence from Pharmaceutical Markets
Quality Regulation and Competition: Evidence from Pharmaceutical Markets
Date Written: September 26, 2018
Abstract
We study the effects of quality regulation on market outcomes by exploiting the staggered phase-in of bioequivalence requirements for generic drugs in Chile. We estimate that the number of drugs in the market decreased by 25%, average paid prices increased by 10%, and total sales decreased by 20%. These adverse effects were concentrated among small markets. Our results suggest that the intended effects of quality regulation on price competition through increased (perceived) quality of generics—and therefore reduced vertical differentiation—were overturned by adverse competitive effects arising from the costs of complying with the regulation.
Keywords: Quality regulation, competition, bioequivalence, generic pharmaceuticals
JEL Classification: I11, L11, L15, L65
Suggested Citation: Suggested Citation